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Introduction: The infiltration of FOXP3+ regulatory T cells into invasive tumors has been reported to be associated
with survival in a variety of cancers. The prognostic significance of FOXP3+ tumor-infiltrating lymphocytes (TILs) in
breast cancer, however, remains controversial.
Methods: FOXP3+ TILs were assessed by immunohistochemistry on tissue microarrays constructed from a
well-defined cohort of 3,992 breast cancer patients linked to detailed demographic, biomarker, treatment and
outcome data. Survival analyses were performed using the Kaplan-Meier function and Cox proportional hazards
regression models to evaluate the association of FOXP3+ TILs with breast cancer-specific survival, stratified by
intrinsic subtype and cytotoxic T-cell infiltration status (as defined by CD8 immunohistochemistry).
Results: The presence of high numbers of FOXP3+ TILs was significantly associated with young age, high grade,
estrogen receptor (ER) negativity, concurrent CD8+ cytotoxic T-cell infiltration, and human epidermal growth factor
receptor-2 positive (HER2+)/ER− and core basal subtypes. On multivariate survival analysis, a high level of FOXP3+
TILs was significantly associated with poor survival in ER+ breast cancers that lacked CD8+ T-cell infiltrates (hazard
ratio (HR) = 1.30, 95% confidence interval (CI) = 1.02 to 1.66). However, in ER− breast cancers, FOXP3+ TILs were
strongly associated with improved survival in the HER2+/ER− subgroup, particularly in those with co-existent
CD8+ T-cell infiltrates (HR = 0.48, 95% CI = 0.23 to 0.98), for which the presence of high levels of FOXP3+ TILs was
independent of standard clinical prognostic factors.
Conclusions: FOXP3+ regulatory TILs are a poor prognostic indicator in ER+ breast cancer, but a favorable
prognostic factor in the HER2+/ER− subtype. The prognostic value of FOXP3+ TILs in breast cancer differs
depending on ER and HER2 expression status and CD8+ T-cell infiltration.* Correspondence: torsten@mail.ubc.ca
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FOXP3 is a forkhead box transcription factor, containing
a DNA-binding domain that can recruit both transcrip-
tional activator and repressor complexes to target genes
[1]. This transcription factor plays an important role in
the development and function of immune regulatory T
cells (Tregs), and can be used as a specific biomarker for
the identification of Tregs within an inflammatory infiltrate
[2]. Tregs are critical for the maintenance of self-tolerance.
There is also mounting evidence that these cells play a
central role in immune tolerance to tumor cells by several
mechanisms, including inhibiting effector cytotoxic T-cell
lymphocytes by reversibly interfering with the release of
lytic granules by CD8+ T cells, thereby impeding target cell
lysis [3]. Effective evasion of the immune system by tumor
cells is necessary during oncogenesis, tumor progression
and metastatic spread. Increased activity of Tregs has been
linked with a poor immunological response to tumor anti-
gens and is thought to represent a critical mechanism of
immune evasion by tumors. The tumor microenvironment
has been reported to contain a rich milieu of molecules
capable of increasing the number of FOXP3+ Tregs by
several possible mechanisms, including driving CD4+
T-helper cells to develop into FOXP3+ Tregs, recruiting
existing FOXP3+ Tregs to the tumor site, and inducing
the expansion of resident Tregs. This tumor-induced in-
crease in FOXP3+ Tregs represents a potential barrier to
attempts at cancer immunotherapy [4,5].
Studies addressing the prognostic significance of
FOXP3+ Tregs have shown conflicting results. The pres-
ence of FOXP3+ tumor-infiltrating lymphocytes (TILs)
has been reported to be associated with poor clinical out-
come in a variety of cancer types, including prostatic,
lung, hepatocellular and renal cell carcinomas [6-10], indi-
cating that cancer patients may benefit from blocking the
capacity of tumor cells to recruit Tregs. Conversely, other
studies have found that FOXP3+ TILs correlate with fa-
vorable prognosis in colorectal, gastric, ovarian and head
and neck carcinomas [11-15]. These discrepant prognostic
associations of FOXP3+ TILs reflect the complexity of
biological processes affecting the host immunological
response to tumoral tissue – in some tumors, immune in-
filtrates are recruited by tumor cells and facilitate tumor
spread, whereas in other tumors immune infiltrates reflect
a host anti-tumor reaction. The type of T cell present may
help distinguish between these types of responses, but this
requires subtyping of TILs into regulatory (FOXP3+) and
cytotoxic (CD8+) populations. For example, we recently
showed that the presence of CD8+ cytotoxic T-cell infil-
trates in breast cancer is a good prognostic factor in basal
breast cancers, but not in the other intrinsic molecular
subtypes of breast cancer [16].
Even within breast cancer, the prognostic significance of
FOXP3+ TILs has been widely debated. Recent studieshave reported that FOXP3+ T-cell infiltration is associated
with poor clinical outcome [17-22], whereas others found
no significant prognostic role for FOXP3+ infiltration in a
large series of breast cancers [23]. Indeed, some recent
evidence suggests that FOXP3+ TILs could actually be a
favorable survival indicator in certain subgroups. A recent
study, using a cohort of 175 estrogen receptor (ER)-nega-
tive breast cancers found that FOXP3+ TILs were positively
correlated with the concurrent presence of CD8+ TILs,
and were an independent good prognostic factor in ER-
negative breast cancer [24]. Another recent study reported
that FOXP3+ TILs were a significant and independent
factor associated with improved overall survival and pro-
gression-free survival in triple-negative breast cancer [25].
The properties of FOXP3+ TILs may be affected by the
tumor microenvironment, thus the prognostic value of
FOXP3+ TILs could possibly be influenced by molecular
subtype and interactions with other immune cells. To
date, few studies have had sufficient power to investigate
the prognostic effect of the interaction of FOXP3+ TILs
with molecular subtypes or different types of immune
response in breast cancer.
We implemented this study to evaluate the prognostic
significance of FOXP3+ TILs, in a population-based breast
cancer cohort with long-term follow-up and detailed
biomarker data defining the main intrinsic molecular




The study population has been previously described
[16,26,27]. In brief, the primary cohort in this study
includes 3,992 female patients diagnosed with invasive
breast cancer between 1986 and 1992 in the province of
British Columbia, representing roughly 20% of all patients
diagnosed with breast cancer in the province during that
time period. The mean age of the population at diagnosis
of breast cancer was 58.9 years (range, 23 to 95 years).
The median follow-up length was 12.6 years (range, 0.1 to
18.5 years). Basic clinical and pathological characteristics
of the study cohort are summarized in Table 1. This study
and our access to the de-identified data were approved by
the Clinical Research Ethics Board of the University of
British Columbia and British Columbia Cancer Agency.
No informed consent was needed as anonymized archival
specimens were used in this study, according to the
Canadian Tri-Council Policy Statement for ethical research
involving human subjects.
Immunohistochemistry
Archival formalin-fixed paraffin-embedded tissue blocks
for each of the 3,992 patients were retained in the cen-
tralized provincial laboratory at the Vancouver General
Table 1 Clinicopathologic characteristics and distribution of FOXP3+ intratumoral lymphocytes (iTILs) in the study
population
Characteristics Number of patients FOXP3+ iTILs (≥2)
(%) Prevalence % P value
Age at diagnosis (year) <0.001
<40 294 (7.4) 41.6 (106/255)
40-49 844 (21.1) 38.5 (264/685)
50-65 1,425 (35.7) 29.5 (350/1186)
>65 1,429 (35.8) 27.0 (311/1150)
Grade <0.001
1 (well differentiated) 209 (5.2) 16.3 (25/153)
2 (moderately well or partially differentiated) 1,563 (39.2) 23.7 (305/1288)
3 (poorly differentiated) 2,040 (51.1) 38.9 (661/1699)
Unknown 180 (4.5)
Tumor size (cm) 0.201
≤2 2,078 (52.1) 30.2 (512/1697)
>2-5 1,667 (41.8) 33.1 (461/1394)
> 5 221 (5.5) 29.8 (50/168)
Unknown 26 (0.6)
Nodal status 0.003
Negative 2,265 (56.7) 29.4 (545/1856)
Positive 1,719 (43.1) 34.2 (484/1414)
Unknown 8 (0.2)
Lymphovascular invasion (LVI) 0.218
Negative 2,106 (52.8) 30.3 (522/1720)
Positive 1,710 (42.8) 32.4 (461/1423)
Unknown 176 (4.4)
AJCC stage 0.003
I 1,393 (34.9) 27.7 (314/1132)
II 2,255 (56.5) 33.7 (630/1872)
III 317 (7.9) 32.2 (82/255)
Unknown/missing 27 (0.7)
Adjuvant systemic therapy (AST)* <0.001
No AST 1,676 (42.0) 29.0 (402/1386)
Tamoxifen only 1,276 (32.0) 27.7 (287/1037)
Chemotherapy only 727 (18.2) 40.6 (245/603)
Tamoxifen + chemotherapy 297 (7.4) 38.8 (92/237)
Other 16 (0.4) 35.7 (5/14)
ER <0.001
Negative 1,200 (30.1) 42.7 (388/909)
Positive (≥1% nuclei stained) 2,761 (69.1) 27.2 (641/2354)
Uninterpretable/missing 31 (0.8)
HER2 <0.001
Negative 3,316 (83.1) 29.9 (830/2779)
Positive 498 (12.5) 42.4 (184/434)
Uninterpretable/missing 178 (4.4)
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Table 1 Clinicopathologic characteristics and distribution of FOXP3+ intratumoral lymphocytes (iTILs) in the study
population (Continued)
Subtype <0.001
Luminal A 1,518 (38.0) 20.8 (275/1325)
Luminal B 829 (20.8) 36.8 (276/749)
Luminal/HER2 224 (5.6) 39.5 (79/200)
Luminal not further assigned 244 (6.1) 19.5 (29/149)
HER2+/ER– 250 (6.3) 45.9 (102/222)
TNP 630 (15.8) 42.2 (226/535)
Core basal 330 (8.3) 54.0 (163/302)
5NP 162 (4.1) 36.5 (50/137)
TNP not assignable 138 (3.4) 39.5 (34/86)
Unassignable 297 (7.4) 21.5 (23/107)
CD8+ iTIL <0.001
0 2,299 (57.6) 19.6 (410/2094)
≥1 1,104 (27.6) 56.6 (591/1044)
Uninterpretable/missing 589 (14.8)
Total 3,992 (100) 31.5 (1031/3277)
*Chemotherapy was methotrexate, cyclophosphamide, 5-fluorouracil (CMF), doxorubicin and cyclophosphamide (AC) or doxorubicin, cyclophosphamide,
5-fluorouracil (FAC). Trastuzumab was not available to these patients. 5NP, five-marker negative phenotype; AJCC, American Joint Committee on Cancer; ER,
estrogen receptor; HER2, human epidermal growth factor receptor-2; iTILs, intratumoral tumor-infiltrating lymphocytes; TNP, triple-negative phenotype.
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time period. Hematoxylin and eosin-stained slides from
these blocks were reviewed by two pathologists to iden-
tify the invasive breast carcinoma area, and the represen-
tative areas containing the most densely cellular viable
invasive breast carcinoma tissue were chosen for cor-
ing. Tissue microarrays (TMAs) were constructed from
these samples and were assessed by immunohistochemical
(IHC) staining for ER, progesterone receptor (PR), human
epidermal growth factor receptor-2 (HER2), Ki67, epi-
dermal growth factor receptor (EGFR), cytokeratins 5/6
(CK5/6) and CD8 as previously described [16,26,28-32].
Breast cancer subtypes were defined by the IHC ex-
pression profile of ER, PR, HER2 (reported as per the
2007 American Society of Clinical Oncology/College of
American Pathologists (ASCO/CAP) guidelines) [33],
Ki67, EGFR and CK5/6 as previously described [16,29]
and were categorized in Table 1. Assessment of CD8+
TILs has been previously reported [16]. IHC staining
for FOXP3+ TILs was performed using the anti-human
FOXP3 monoclonal mouse antibody (clone 236A/E7,
(Abcam, Cambridge, MA, USA) dilution 1:20) according
to the manufacturer’s instruction. The expected nuclear
staining pattern was optimized on benign lymph node tis-
sue, which was also used as the positive control for each
batch and to assess technical consistency of staining
between batches. Images of the FOXP3-stained TMA
cores are available at our TMA image website [34].FOXP3+ TIL measurement
Scoring of FOXP3+ TILs was performed using digitally
scanned TMA slides by a single pathologist blinded to
the results of other markers, clinical characteristics and
outcomes of the patients. FOXP3+ ‘intratumoral’ tumor-
infiltrating lymphocytes (iTILs) were defined as FOXP3-
stained lymphocytes present within the malignant epithe-
lial cell nests, while FOXP3+ ‘stromal’ tumor-infiltrating
lymphocytes (sTILs) were defined as FOXP3-stained lym-
phocytes in the peritumoral stroma, lacking direct contact
with the epithelial cancer cells. The counts of combined
iTILs and sTILs were recorded as ‘total’ FOXP3+ tumor-
infiltrating lymphocytes (tTILs) [16,35]. To test the repro-
ducibility of our scoring system, 281 cases were randomly
selected from the whole cohort, and FOXP3+ iTILs and
sTILs were rescored by the same pathologist, as well as by
a second pathologist blinded to the original scores. We
observed high reproducibility of FOXP3+ TILs scoring by
the same scorer (Pearson correlation coefficient = 0.91 for
FOXP3+ iTILs and 0.97 for FOXP3+ sTILs), and between
the two scorers (intraclass correlation coefficient = 0.88
for FOXP3+ iTILs and 0.90 for FOXP3+ sTILs).
Statistical analysis
Statistical analyses were performed using SPSS version
21.0 (IBM Corp, Armonk, NY, USA) and R version
2.11.1 [36]. The prespecified primary endpoint of this
study was breast cancer-specific survival (BCSS), defined
Liu et al. Breast Cancer Research 2014, 16:432 Page 5 of 12
http://breast-cancer-research.com/content/16/5/432as the time from the date of initial diagnosis of breast
cancer to the date of death attributed to breast cancer.
Death from another cause or alive at end of follow-up
were treated as censored events. We also performed
supplementary analyses using relapse-free survival (RFS)
as the outcome. RFS time was defined as the number of
years from the date of diagnosis of breast cancer to the
date of any type of relapse of the disease. Survival curves
were generated using the Kaplan-Meier method, and
BCSS differences among subgroups were evaluated for
significance using the log-rank test. Cox proportional
hazards regression models were built for multivariate
survival analyses to estimate the hazard ratio (HR) of
FOXP3+ TILs adjusted by potential confounding factors,
including age at diagnosis, tumor grade, tumor size,
lymph node status, lymphovascular invasion, and intrinsic
subtype. The Wald test was used to evaluate the signifi-
cance of individual coefficients in the models. Propor-
tional hazard assumptions were examined by smoothed
rescaled residuals plots. Interaction between FOXP3+ and
CD8+ TILs, with respect to the association with survival
outcome, was tested by building Cox regression models at
different status of CD8+ iTILs, and then evaluating the
hazard ratios of FOXP3+ TILs. The prespecified cutoff
point for CD8+ iTIL (0 vs. ≥1) used for the analyses was
validated in our previous studies [16,35]. All tests were
two-sided with a significance level at α = 0.05.
Repeated random subsampling training test was used
to identify and validate an optimal cutoff point for
FOXP3+ TILs by means of receiver operating characteris-
tic (ROC) curve analysis [37] and Youden Index, using the
10-year BCSS as the endpoint, as described in our previ-
ous study [16]. Briefly, ROC curves were used to show the
sensitivity and specificity for the 10-year BCSS for each
value of FOXP3+ TILs imputed into the equation. The
training set was randomly selected to include 50% of the
total study population and was used to identify an optimal
cutoff point by ROC analysis, which was then tested on
the remaining 50% (test set) of the study population. The
Youden Index was applied to determine if the selected
cutoff was valid in the test set. This procedure was repeated
100 times to ensure robustness (Table S1 in Additional
file 1). Since BCSS is a time to event endpoint, we also
used X-tile software (version 3.6.1, Yale University School
of Medicine, New Haven, CT, USA) to validate the se-
lected cutoff points. The optimal cutoffs for FOXP3+ TILs
identified in these analyses were 2 for iTILs, 3 for sTILs
and 4 for tTILs. In this study, FOXP3+ iTILs were catego-
rized as low when <2 FOXP3+ iTILs were identified in a
single tissue core, and as high when ≥2 FOXP3+ iTILs
were identified. FOXP3+ sTILs were categorized as low
when <3 FOXP3+ sTIL were identified in a single tissue
core and as high when ≥3 FOXP3+ sTILs were identified.
Lastly, FOXP3+ tTILs were categorized as low when <4FOXP3+ tTIL were identified in a single tissue core and
as high when ≥4 FOXP3+ tTILs were identified.
Results
Distributions and prognosis of FOXP3+ TILs in the whole
study cohort
Of the 3,992 breast cancer patients in the original study
cohort, 3,277 (82.1%) cases had intact 0.6 mm TMA
cores containing infiltrating breast carcinoma and were
interpretable for FOXP3 staining. At least one FOXP3+
iTIL (intratumoral) was present in 45.0% and at least
one sTIL (stromal) in 74.8% of the 3,277 tumor cases.
Both FOXP3+ iTILs and sTILs were present in the same
core in 42% of cases (sample images shown in Figure S1
in Additional file 2). The median number of FOXP3+
TILs was 0 for iTILs (interquartile range IQR, 0 to 2), 3
for sTILs (IQR, 3 to 11), and 4 for tTILs (IQR, 4 to 13).
In this paper, we report the results from the FOXP3+
iTIL primary analysis as this measurement is fastest and
simple to perform, and was the primary analysis previ-
ously applied to CD8+ TILs on this population; results
from stromal and total categorizations of TILs were gener-
ally similar. Tumors with ≥2 FOXP3+ iTIL were signi-
ficantly correlated with young age, high grade, positive
nodal status, the presence of CD8+ iTILs, ER negativity,
and with the HER2+/ER − and the core basal intrinsic sub-
groups (Table 1).
To assess the prognostic value of FOXP3+ iTILs in
the whole study cohort, we built Cox proportional haz-
ards regression models to estimate the hazard ratio of
FOXP3+ iTIL for breast cancer specific survival. Neither
the univariate nor multivariate Cox regression analyses
showed a significant association of FOXP3+ iTIL with
BCSS in the whole cohort of unselected breast cancer pa-
tients (univariate analysis: HR = 1.13, 95% confidence inter-
val (CI) = 0.99 to 1.29; multivariate analysis: HR = 0.89, 95%
CI = 0.77 to 1.02; full details in Table S2 in Additional
file 1). Kaplan-Meier survival analysis revealed that the
prognostic significance of FOXP3+ iTILs was subtype-
specific and was associated with opposite prognostic
effects in ER positive versus ER negative tumors. As
shown in Figure 1, FOXP3+ iTILs were an indicator of
poor survival in ER + tumors, but a favorable prognostic
indicator in ER − breast cancers, indicating that the
interaction of FOXP3+ iTILs with ER status could miti-
gate the prognostic effect of FOXP3+ TILs in the unstrati-
fied breast cancer population.
Prognosis of FOXP3+ iTILs in ER positive breast cancer
Although the Kaplan-Meier curves (Figure 1) showed that
a high level of FOXP3+ iTILs (≥2) was significantly asso-
ciated with worse BCSS in ER + breast cancer (P = 0.015),
on multivariate Cox regression analysis the hazard ratio
for FOXP3+ iTILs was not independently significant in




































iTIL < 2  n = 1711 event = 434
iTIL ≥ 2  n = 640  event = 194
iTIL ≥ 2  n = 388 event = 130
iTIL < 2  n = 521 event = 201
iTIL < 2  15-year BCSS 70% (95% CI, 68-72)                                   iTIL < 2  15-year BCSS 58% (95% CI, 52-64)
iTIL ≥ 2  15-year BCSS 66% (95% CI, 62-70)                                   iTIL ≥ 2  15-year BCSS 66% (95% CI, 60-72)
ER+; Log-rank p = 0.014                                                                  ER−; Log-rank p = 0.123 
Figure 1 Breast cancer-specific survival (BCSS) stratified by FOXP3+ iTILs in ER-positive and ER-negative breast cancers. (a) ER+, (b) ER–.
ER, estrogen receptor; iTILs, intratumoral tumor-infiltrating lymphocytes.
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when adjusted for age, tumor grade, tumor size, nodal sta-
tus, and lymphovascular invasion (Table 2). We then eval-
uated the prognostic effect of the interaction of FOXP3+
iTILs with CD8+ cytotoxic T-cell infiltrates in ER + breast
cancers by building multivariate Cox regression models
stratified by CD8+ iTIL status. The stratified multivariate
regression analyses showed that the poor prognostic effect
of FOXP3+ iTILs in the ER + group was only detected in
those with CD8+ iTIL = 0 (HR = 1.30, 95% CI = 1.02 to
1.66; P = 0.03, Table 2).Table 2 Estimates of hazard ratio with multivariate analysis in
Variable ER + (n = 2166) ER+/CD8
HR (95% CI) P HR (95%
Age 1.06 0.536 1.03
≥50 vs. <50 (0.88 - 1.27) (0.82 - 1.
Grade 1.67 <0.001 1.67
3 vs. (1 and 2) (1.41 - 1.99) (1.35 - 2.
Tumor size 1.76 <0.001 1.75
>2 cm vs. ≤2 cm (1.48 - 2.10) (1.41 - 2.
Nodal status 1.98 <0.001 2.18
Positive vs. negative (1.63 - 2.40) (1.72 - 2.
LVI 1.30 0.007 1.33
Positive vs. negative (1.07 - 1.57) (1.05 - 1.
FOXP3+ iTIL 1.14 0.138 1.30
≥2 vs. <2 (0.96 - 1.37) (1.02 - 1.
CI, confidence interval; ER, estrogen receptor; HR, hazard ratio; iTIL, intratumoral tumPrognosis of FOXP3+ iTILs in ER negative breast cancer
Because standard six-marker IHC analysis, as used in
this study, can subdivide ER– breast cancers into the
distinct subtypes of HER2+/ER–, core basal and five-
marker negative phenotype (5NP), each with distinct
underlying biology, we assessed the prognosis of FOXP3+
iTILs in these subtypes separately in a preplanned stra-
tification. The Kaplan-Meier analysis showed that, in the
HER2+/ER– and core basal intrinsic subtypes, the differ-
ences in BCSS were significant between patients with high
and low FOXP3+ iTILs (Figure 2a and b). Cases in theseER + breast cancers, with different CD8+ iTIL status
+ iTIL = 0 (n = 1474) ER+/CD8+ iTIL ≥1 (n = 624)
CI) P HR (95% CI) P
0.803 1.14 0.449
29) (0.82 - 1.59)
<0.001 1.71 0.001
05) (1.24 - 2.36)
<0.001 1.66 0.002
16) (1.21 - 2.27)
<0.001 1.51 0.017
77) (1.08 - 2.13)
0.020 1.24 0.209
68) (0.89 - 1.74)
0.032 1.00 0.978
66) (0.74 - 1.34)





















































Years of follow-up 
Years of follow-up 
iTIL < 2  15-year BCSS 46% (95% CI, 36-56) 
iTIL ≥ 2  15-year BCSS 63% (95% CI, 53-73)
HER2+/ER−; Log-rank p = 0.017 
iTIL < 2  15-year BCSS 55% (95% CI, 47-63)
iTIL ≥ 2  15-year BCSS 68% (95% CI, 60-76)
Core basal; Log-rank p = 0.018
iTIL < 2  15-year BCSS 70% (95% CI, 60-80)
iTIL ≥ 2  15-year BCSS 69% (95% CI, 55-83)
5NP; Log-rank p = 0.631
iTIL ≥ 2  n = 102 event = 37 
iTIL < 2  n = 120 event = 64
iTIL < 2  n = 87 event = 24
iTIL ≥ 2  n = 50 event = 15
iTIL ≥ 2  n = 163 event = 51 
iTIL < 2  n = 139 event = 61
b
c
Figure 2 Breast cancer-specific survival (BCSS) stratified by
FOXP3+ iTILs in different subtypes of ER– breast cancer.
(a) HER2+/ER–, (b) core basal, and (c) five-marker negative phenotype
(5NP) subgroup. ER, estrogen receptor; HER2, human epidermal
growth factor receptor-2; iTILs, intratumoral tumor-infiltrating
lymphocytes.
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(that is FOXP3+ iTIL ≥2) had significantly better sur-
vival than those with FOXP3+ iTIL <2. However, in
the 5NP subtype, constituting cases labeled as ‘triple
negative’ but not expressing positive markers of the
basal group, no such association or even trend was ob-
served (Figure 2c).
We assessed the prognostic effect of the interaction
between FOXP3+ (regulatory) and CD8+ (cytotoxic)
iTILs in the HER2+/ER– and core basal subtypes, by
performing Kaplan-Meier survival analyses incorporating
the CD8+ iTILs status. It was demonstrated that the
improved prognosis associated with FOXP3+ iTIL was
only significant in the HER2+/ER– subtype when CD8+
iTILs were concurrently present. Among these cases, at
15 years of follow-up, patients with FOXP3+ iTIL ≥2
had a 28% higher cumulative survival rate than those with
FOXP3+ iTIL <2 (Figure 3b). No significant associations
were observed in other subgroups (Figure 3a, c and d),
despite larger numbers of patients.
We further built multivariate Cox regression models in-
cluding the conventional clinical co-variables to assess the
independent prognostic value of the regulatory FOXP3+
iTILs in the major subtypes of ER-negative breast cancers,
stratified by the presence or absence of concurrent
cytotoxic CD8+ iTILs. Table 3 showed that in the
HER2+/ER– subtype, when CD8+ iTILs are present,
patients with FOXP3+ iTIL ≥2 had a significantly
(52%, 1 to 0.48) higher probability of survival than
those with FOXP3+ iTIL <2. Although the favorable effect
was also observed in those lacking this evidence of
concurrent CD8+ T-cell infiltration, the magnitude of dif-
ference was smaller and not significant (HR = 0.84, 95%
CI = 0.48 to 1.46, P = 0.36). However, in the core basal
subtype, although we observed a significant favorable
prognostic effect of FOXP3+ iTILs in general, after taking
CD8+ iTIL into account, the effect became insignificant.
More interestingly, both the univariate Kaplan-Meier
function and multivariate Cox regression analyses showed
that FOXP3+ iTILs did not have apparent prognostic
effect in the core basal cases with CD8+ T-cell infiltrates
(HR = 0.93, 95% CI = 0.43 to 2.00; P = 0.85). The favorable
prognostic effect of FOXP3+ iTILs observed in the whole
core basal subtype could be primarily attributable to the
concurrent high presence of CD8+ iTILs, as observed in
our previous study [16].











   
   
   
   
   
   
   
   
   
   
   
   
   
   



























iTIL ≥ 2  n = 61 event = 19
 
iTIL < 2  n = 27  event = 16
iTIL ≥ 2  n = 39 event = 17
iTIL < 2  n = 89  event = 47
iTIL < 2  15-year BCSS 47% (95% CI, 37-57)                                   iTIL < 2  15-year BCSS 40% (95% CI, 20-60)
iTIL ≥ 2  15-year BCSS 56% (95% CI, 40-72)                                   iTIL ≥ 2  15-year BCSS 68% (95% CI, 56-80)

























   
   
   
   
   
   
   
   
   
   
   
   
   
   












c                                                                   d
Years of follow-up                                                        Years of follow-up
iTIL ≥ 2  n = 57 event = 23
iTIL < 2  n = 91  event = 46
iTIL ≥ 2  n = 104 event = 27
iTIL < 2  n = 41  event = 11
iTIL < 2  15-year BCSS 49% (95% CI, 39-59)                                   iTIL < 2  15-year BCSS 72% (95% CI, 58-86)
iTIL ≥ 2  15-year BCSS 60% (95% CI, 46-74)                                   iTIL ≥ 2  15-year BCSS 73% (95% CI, 65-81)
                                                                                                          
Core basal/CD8+ iTIL = 0; Log-rank p = 0.171                                 Core basal/CD8+ iTIL ≥ 1; Log-rank p = 0.968 
Figure 3 Breast cancer-specific survival (BCSS) by FOXP3+ iTILs in HER2+/ER– and core basal intrinsic subtypes, stratified by CD8+ iTILs
status. (a) HER2+/ER– with no CD8+ iTILs, (b) HER2+/ER– with presence of CD8+ iTILs, (c) core basal with no CD8+ iTILs, and (d) core basal with
presence of CD8+ iTILs. ER, estrogen receptor; HER2, human epidermal growth factor receptor-2; iTILs, intratumoral tumor-infiltrating lymphocytes.
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The infiltration of tumors by regulatory T cells (defined
as FOXP3+ TILs) has been reported to be associated
with patient survival in a variety of cancers, but its prog-
nostic value remains controversial. We evaluated the
prognostic effect of FOXP3+ TILs in breast cancer, using
a large population-based breast cancer cohort with long
clinical follow-up. In addition to assessing the independ-
ent prognostic value of FOXP3+ TILs, adjusted by con-
ventional clinicopathological confounding factors, we
also investigated the prognostic effect of the interaction
between regulatory and cytotoxic T-cell infiltrates (defined
as CD8+ TILs) in different molecular subtypes of breast
cancer, a novel analysis made possible by the large sample
size and availability of concurrent biomarker data. Resultsfrom this study demonstrate that, in breast cancer, the
presence of high levels of FOXP3+ TILs is associated with
young age, high grade, positive nodal status, concurrent
CD8+ T-cell infiltrates, and ER negativity (including both
the HER2+/ER– and core-basal subtypes). In ER + breast
cancer, high FOXP3+ TILs were significantly associated
with poor clinical outcome. When ER + tumors did not
display concurrent CD8+ lymphocyte infiltration, patients
with high levels of FOXP3+ TILs had 30% higher cumula-
tive death rates than those with low FOXP3+ TILs. How-
ever, in ER– group, the prognostic effect of FOXP3+ TILs
differed by intrinsic subgroup, depending on the presence
of CD8+ T-cell infiltration. In HER2+/ER– breast cancer,
the multivariate analysis indicates that high FOXP3+
lymphocyte infiltration is a significant, independent and
Table 3 Estimates of hazard ratio with multivariate analysis in HER2+/ER– and core basal subtypes, stratified by CD8+
iTIL status
Variable Whole subgroup With CD8+ iTIL = 0 With CD8+ iTIL ≥ 1
HR (95% CI) P HR (95% CI) P HR (95% CI) P
HER2+/ER–
Age 1.13 0.573 1.09 0.741 1.12 0.784
≥50 vs. <50 (0.74 - 1.73) (0.65 - 1.84) (0.50 - 2.50)
Grade 2.23 0.007 2.05 0.039 2.55 0.134
3 vs. (1 and 2) (1.24 - 4.01) (1.04 - 4.07) (0.75 - 8.65)
Tumor size 1.67 0.026 1.43 0.198 2.53 0.025
>2 cm vs. ≤2 cm (1.06 - 2.61) (1.83 - 2.48) (1.13 - 5.67)
Nodal status 1.95 0.008 1.20 0.588 3.87 0.002
Positive vs. negative (1.19 - 3.21) (0.62 - 2.35) (1.67 - 8.96)
LVI 1.34 0.250 1.47 0.261 1.56 0.268
Positive vs. negative (0.82 - 2.19) (0.75 - 2.85) (0.71 - 3.40)
FOXP3+ iTIL 0.71 0.104 0.84 0.528 0.48 0.047
≥2 vs. <2 (0.46 - 1.07) (0.48 - 1.49) (0.23 - 0.98)
Core basal
Age 1.01 0.957 0.77 0.301 1.53 0.245
≥50 vs. <50 (0.68 - 1.50) (0.47 - 1.26) (0.75 - 3.12)
Grade 1.30 0.417 1.55 0.257 1.91 0.387
3 vs. (1 and 2) (0.69 - 2.44) (0.73 - 3.28) (0.44 - 8.22)
Tumor size 1.62 0.020 2.81 <0.001 0.77 0.470
>2 cm vs. ≤2 cm (1.08 - 2.43) (1.67 - 4.72) (0.38 - 1.57)
Nodal status 2.37 <0.001 2.95 <0.001 1.64 0.212
Positive vs. negative (1.53 - 3.66) (1.68 - 5.17) (0.75 - 3.56)
LVI 1.37 0.159 0.86 0.604 3.60 0.003
Positive vs. negative (0.88 - 2.13) (0.49 - 1.51) (1.56 - 8.29)
FOXP3+ iTIL 0.53 0.002 0.66 0.130 0.93 0.845
≥2 vs. <2 (0.36 - 0.79) (0.39 - 1.13) (0.43 - 2.00)
CI, confidence interval; ER, estrogen receptor; HR, hazard ratio; HER2, human epidermal growth factor receptor-2; iTIL, intratumoral tumor-infiltrating lymphocyte;
LVI, lymphovascular invasion.
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CD8+ T-cell infiltrates. In this subgroup, those with high
levels of FOXP3+ TILs had 52% higher probability of
survival than those with low FOXP3+ TILs. However, in
the core-basal subgroup, although high levels of FOXP3+
lymphocyte infiltration was associated with improved sur-
vival in general, the presence of CD8+ T-cell infiltrates ap-
peared to be the stronger and more important favorable
prognostic factor.
The prognostic associations of FOXP3+ TILs could be
affected by tumor microenvironment, including tumor
site, histologic and molecular subtype, and different
types of immune response, all of which may interactively
influence clinical outcome of cancer patients. In general,
patients with ER + breast cancers experience better clin-
ical outcome than those with ER– tumors, but not all
ER + breast cancer patients have good survival. It wasreported that FOXP3+ TILs were associated with poor
clinical outcome in ER + breast cancer [17,23]. The
multivariate analysis from our study confirms that, in
ER + breast cancer, FOXP3+ regulatory TILs are an indi-
cator for poor survival, at least in those tumors lacking
concurrent cytotoxic CD8+ T-cell infiltration. One pos-
sible explanation consistent with these findings is that
FOXP3+ TILs reflect tumor-induced immune evasion in
ER + breast cancers. Although patients with ER– tumors
usually have poor survival, some biological signatures
serve as favorable prognostic indicators among ER– breast
cancers. Studies with clinical and gene expression data
demonstrate that an immune response is significantly
associated with improved prognosis among ER– breast
cancers [38-41]. In our study, FOXP3+ TILs were found
to be a favorable indicator of survival in ER– breast can-
cer, which is also consistent with the findings from other
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http://breast-cancer-research.com/content/16/5/432recently published studies [24,25]. Cause and effect cannot
be determined from this type of association study, but for
the HER2+/ER– group at least one interpretation con-
sistent with the data is that FOXP3+ TILs are induced
secondarily by a robust antitumor CD8+ TIL response.
Until now, comparatively few studies have been pow-
ered to assess if different categories of tumor-infiltrating
lymphocytes influence clinical outcomes in different
breast cancer molecular subtypes. Our study indicates
that the infiltration of FOXP3+ lymphocytes not only
has distinctive prognostic associations within different
subtypes of breast cancer, but also interacts with cyto-
toxic T-cell infiltrates in their association with patient
survival. Our multivariate analyses stratified for presence
or absence of CD8+ T-cell infiltration demonstrated that
the favorable prognostic effect of FOXP3+ TILs in ER–
breast cancer was only significant and independent in
those having HER2+/ER– tumors with concurrent CD8+
T-cell infiltrates. In the core basal subtype, the favorable
prognostic effect associated with a TIL immune response
may be primarily due to CD8+ T-cell infiltration, which
may be counteracted when FOXP3+ Tregs are also
present. Despite our large sample size and event rate
with long follow-up, these subgroup analyses still have
limited power, and as a retrospective cohort analysis will
require external validation or incorporation into meta-
analyses to increase the level of evidence for these
results.
The prognostic significance of immune responses in
breast cancer is controversial. Most of the studies
reporting that FOXP3+ TILs are an indicator of poor
prognosis in breast cancer applied unstratified survival
analyses [17,19] and might be expected to largely reflect
the majority ER + population, possibly confounded by an
opposite association in ER– cases. Recent studies, using
large breast cancer cohorts, have consistently demon-
strated that cytotoxic T-cell infiltration plays different
prognostic roles in different molecular subtypes [16,35,42].
To our knowledge, ours is the first study with sufficient
power to evaluate the prognosis of these interactions strati-
fied by subtype and cytotoxic vs. regulatory lymphocyte
infiltration. Some studies have applied ratios of CD8+:
FOXP3+ TILs to evaluate the prognostic effect of immune
response in breast cancer, and reported that those with a
ratio of CD8+: FOXP3+ TILs ≥1 had better survival than
those with ratios <1 [21,24,43]. The results from our study
suggest that both FOXP3+ and CD8+ T-cell infiltration
have distinctive prognostic implications in different mo-
lecular subtypes of breast cancer. A simple ratio between
FOXP3+ and CD8+ TILs may not be an appropriate uni-
versal prognostic indicator, across biologically different
breast cancer subtypes.
Inconsistency in defining and measuring tumor infiltrat-
ing lymphocytes may also underlie apparently discrepantresearch results. In this study, we used specific immuno-
histochemistry with a widely used mouse monoclonal
anti-human FOXP3 antibody to detect regulatory intratu-
moral and stromal TILs in breast tumor tissue. Both ROC
curve and X-tile methods were applied to define the
optimal cutoff points of FOXP3+ TILs for the survival
analyses. These findings apply to the TMA platform but
would need modification and re-validation to be applied
to whole sections. To confirm the prognosis of FOXP3+
TILs in breast cancer, we also evaluated the association of
FOXP3+ iTIL with relapse-free survival; results were very
similar to those using breast cancer-specific survival as the
outcome (Tables S3-S5 in Additional file 1). Furthermore,
we tested the correlation of FOXP3+ sTILs and tTILs
with patient clinical and pathological characteristics.
As with the primary assessment of intratumoral lym-
phocytes, results demonstrated positive correlations
between presence of high numbers of FOXP3+ sTIL
and tTIL with young age, high grade, positive nodal
status, CD8+ T-cell tumor infiltration, ER negativity,
and with HER2+/ER– and core basal subgroups (Table S6
in Additional file 1).
Although we believe that the measurement of FOXP3
+ TILs and the evaluation of the association of FOXP3+
TILs with breast cancer patient survival are reliable and
form a consistent picture with other reports, there are
some limitations in this study. Studies suggest that
FOXP3 represents the most specific marker for Treg
cells, but some rare subtypes of cytotoxic lymphocytes
may also express FOXP3 [17,44]. This study only assessed
the interaction between FOXP3+ and CD8+ T-cell infil-
tration in breast cancer; further studies need to be done to
differentiate other types of chronic inflammatory infiltra-
tion. Studies have reported that pre-existing immune
responses may fortify the effect of chemotherapy [45,46].
TILs could be a favorable predictive indicator for targeted
trastuzumab therapy [47,48]. The patients in our study
predate the trastuzumab era, and the types of endocrine
and chemotherapy given would be considered out-
dated by contemporary standards of care. An explora-
tory multivariate analysis (Table S7 in Additional file
1) found that pre-existing FOXP3+ Treg infiltration
might be a favorable factor for the group of patients
treated with conventional chemotherapy (for BCSS:
HR = 0.67, 95% CI = 0.50 to 0.89, P = 0.006; for RFS:
HR = 0.69, 95% CI = 0.53-0.90, P = 0.005), but treat-
ment was not randomly assigned in our study cohort.
Formal prospective-retrospective studies of randomized
trials [49], using locked-down assay and interpretation
methodology based on cohort studies such as ours,
would be the next step to determine, with a higher
level of evidence, the relationship between chemo-
therapy, immune infiltrates and clinical outcome of
cancer patients.
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The results from this large study indicate that the prog-
nosis of FOXP3+ regulatory lymphocyte infiltration into
breast tumors differs with the expression status of ER,
HER2 and concurrent CD8+ T-cell infiltration. FOXP3+
TILs are significantly associated with poor survival in
ER + breast cancers lacking cytotoxic T-cell infiltrates.
In contrast, tumor regulatory T-cell infiltration is an
independent and favorable indicator of survival in breast
cancer patients who have HER2+/ER– breast tumors with
CD8+ T-cell infiltrates.
Additional files
Additional file 1: Supplemental tables. Table S1. Shows the selected
cutoffs of TILs from the training set and the mean of the Youden Index
(95% CI) obtained from the test set for each cutoff in the 100-time
repeated runs. Table S2. Demonstrates the detailed results of FOXP3+
iTIL for BCSS from univariate and multivariate Cox regression analysis for
the whole study cohort. Tables S3-S5. Shows the hazard ratios of FOXP3+
iTIL for RFS in the whole study cohort, ER+, HER2+/ER– and core basal
subtypes. Table S6. Shows the distribution and FOXP3+ sTIL and tTIL in
relation to patient clincopathologic characteristics. Table S7. Shows the
hazard ratios of FOXP3+ iTIL for BCSS and RFS in multivariate analysis for
patients treated with chemotherapy.
Additional file 2: FOXP3+ TILs in breast cancer. Figure S1. Shows
some examples of FOXP3+ iTILs and sTILs in a breast cancer tissue
microarray core (scale bar: 50 μm).
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